Cargando…

Adverse drug events associated with vitamin K antagonists: factors of therapeutic imbalance

BACKGROUND: Adverse drug events (ADE) occur frequently during treatment with vitamin K antagonists (AVK) and contribute to increase hemorrhagic risks. METHODS: A retrospective study was conducted over a period of 2 years. Patients treated with AVK and admitted to the emergency room of a tertiary car...

Descripción completa

Detalles Bibliográficos
Autores principales: El-Helou, Nancy, Al-Hajje, Amal, Ajrouche, Rola, Awada, Sanaa, Rachidi, Samar, Zein, Salam, Salameh, Pascale
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3589081/
https://www.ncbi.nlm.nih.gov/pubmed/23467749
http://dx.doi.org/10.2147/VHRM.S41144
_version_ 1782261692235776000
author El-Helou, Nancy
Al-Hajje, Amal
Ajrouche, Rola
Awada, Sanaa
Rachidi, Samar
Zein, Salam
Salameh, Pascale
author_facet El-Helou, Nancy
Al-Hajje, Amal
Ajrouche, Rola
Awada, Sanaa
Rachidi, Samar
Zein, Salam
Salameh, Pascale
author_sort El-Helou, Nancy
collection PubMed
description BACKGROUND: Adverse drug events (ADE) occur frequently during treatment with vitamin K antagonists (AVK) and contribute to increase hemorrhagic risks. METHODS: A retrospective study was conducted over a period of 2 years. Patients treated with AVK and admitted to the emergency room of a tertiary care hospital in Beirut were included. The aim of the study was to identify ADE characterized by a high international normalized ratio (INR) and to determine the predictive factors responsible for these events. Statistical analysis was performed with the SPSS statistical package. RESULTS: We included 148 patients. Sixty-seven patients (47.3%) with an INR above the therapeutic range were identified as cases. The control group consisted of 81 patients (54.7%) with an INR within the therapeutic range. Hemorrhagic complications were observed in 53.7% of cases versus 6.2% of controls (P < 0.0001). No significant difference was noticed between cases and controls regarding the indication and the dose of AVK. Patients aged over 75 years were more likely to present an INR above the therapeutic range (58.2%, P = 0.049). Recent infection was present in 40.3% of cases versus 6.2% of controls (P < 0.0001) and hypoalbuminemia in 37.3% of cases versus 6.1% of controls (P < 0.0001). Treatment with antibiotics, amiodarone, and anti-inflammatory drugs were also factors of imbalance (P < 0.0001). CONCLUSION: Many factors may be associated with ADE related to AVK. Monitoring of INR and its stabilization in the therapeutic range are important for preventing these events.
format Online
Article
Text
id pubmed-3589081
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-35890812013-03-06 Adverse drug events associated with vitamin K antagonists: factors of therapeutic imbalance El-Helou, Nancy Al-Hajje, Amal Ajrouche, Rola Awada, Sanaa Rachidi, Samar Zein, Salam Salameh, Pascale Vasc Health Risk Manag Original Research BACKGROUND: Adverse drug events (ADE) occur frequently during treatment with vitamin K antagonists (AVK) and contribute to increase hemorrhagic risks. METHODS: A retrospective study was conducted over a period of 2 years. Patients treated with AVK and admitted to the emergency room of a tertiary care hospital in Beirut were included. The aim of the study was to identify ADE characterized by a high international normalized ratio (INR) and to determine the predictive factors responsible for these events. Statistical analysis was performed with the SPSS statistical package. RESULTS: We included 148 patients. Sixty-seven patients (47.3%) with an INR above the therapeutic range were identified as cases. The control group consisted of 81 patients (54.7%) with an INR within the therapeutic range. Hemorrhagic complications were observed in 53.7% of cases versus 6.2% of controls (P < 0.0001). No significant difference was noticed between cases and controls regarding the indication and the dose of AVK. Patients aged over 75 years were more likely to present an INR above the therapeutic range (58.2%, P = 0.049). Recent infection was present in 40.3% of cases versus 6.2% of controls (P < 0.0001) and hypoalbuminemia in 37.3% of cases versus 6.1% of controls (P < 0.0001). Treatment with antibiotics, amiodarone, and anti-inflammatory drugs were also factors of imbalance (P < 0.0001). CONCLUSION: Many factors may be associated with ADE related to AVK. Monitoring of INR and its stabilization in the therapeutic range are important for preventing these events. Dove Medical Press 2013 2013-03-01 /pmc/articles/PMC3589081/ /pubmed/23467749 http://dx.doi.org/10.2147/VHRM.S41144 Text en © 2013 El-Helou et al, publisher and licensee Dove Medical Press Ltd This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited.
spellingShingle Original Research
El-Helou, Nancy
Al-Hajje, Amal
Ajrouche, Rola
Awada, Sanaa
Rachidi, Samar
Zein, Salam
Salameh, Pascale
Adverse drug events associated with vitamin K antagonists: factors of therapeutic imbalance
title Adverse drug events associated with vitamin K antagonists: factors of therapeutic imbalance
title_full Adverse drug events associated with vitamin K antagonists: factors of therapeutic imbalance
title_fullStr Adverse drug events associated with vitamin K antagonists: factors of therapeutic imbalance
title_full_unstemmed Adverse drug events associated with vitamin K antagonists: factors of therapeutic imbalance
title_short Adverse drug events associated with vitamin K antagonists: factors of therapeutic imbalance
title_sort adverse drug events associated with vitamin k antagonists: factors of therapeutic imbalance
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3589081/
https://www.ncbi.nlm.nih.gov/pubmed/23467749
http://dx.doi.org/10.2147/VHRM.S41144
work_keys_str_mv AT elhelounancy adversedrugeventsassociatedwithvitaminkantagonistsfactorsoftherapeuticimbalance
AT alhajjeamal adversedrugeventsassociatedwithvitaminkantagonistsfactorsoftherapeuticimbalance
AT ajroucherola adversedrugeventsassociatedwithvitaminkantagonistsfactorsoftherapeuticimbalance
AT awadasanaa adversedrugeventsassociatedwithvitaminkantagonistsfactorsoftherapeuticimbalance
AT rachidisamar adversedrugeventsassociatedwithvitaminkantagonistsfactorsoftherapeuticimbalance
AT zeinsalam adversedrugeventsassociatedwithvitaminkantagonistsfactorsoftherapeuticimbalance
AT salamehpascale adversedrugeventsassociatedwithvitaminkantagonistsfactorsoftherapeuticimbalance